LSE · IXI.L
IXICO plc
£0.12£0.00 (0.0%)
IXICO plc’s quoted price sits in the upper half of its reported 52-week range, 9.62% below the high.
Loading market information…
LSE · OPTI.L · GBp
Stock price, earnings
Quote as of Oct 29, 2026, 09:09 AM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
OptiBiotix Health Plc’s quoted price sits in the lower half of its reported 52-week range, 35.56% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
OptiBiotix Health Plc’s next earnings report is currently expected on Jul 1, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow OptiBiotix Health Plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
OptiBiotix Health Plc, a life sciences enterprise headquartered in York, United Kingdom, specializes in the discovery and advancement of microbiome-modulating technologies. The company formulates distinct microbial strains, innovative compounds, and tailored blends intended for integration into food products, nutritional supplements, and active ingredients. Their groundbreaking work aims to positively influence human physiology and yield substantial health benefits. Among its diverse product portfolio are Slimbiome, a natural ingredient for healthy and satiety-driven weight management, and SlimBiome Medical, a supplemental aid for weight control. Other offerings include CholBiome, a dietary supplement for maintaining healthy cholesterol; Lactobacillus plantarum LPLDL, a probiotic supporting cardiovascular health and overall well-being; LPGOS, a galactooligosaccharide utilized in food applications to mitigate cardiovascular risk factors and enhance general health; WellBiome, a functional fiber and mineral blend designed to bolster gut microbiome diversity and promote wellness; and Sweetbiotix, a sweetener for use in various foods and beverages. Ultimately, OptiBiotix's innovations are designed to prevent and manage prevalent chronic lifestyle diseases, including obesity, high cholesterol, and diabetes. The company was founded in 2012.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£0.12£0.00 (0.0%)
IXICO plc’s quoted price sits in the upper half of its reported 52-week range, 9.62% below the high.
£0.02-£0.00 (-3.95%)
Genflow Biosciences Plc’s quoted price sits in the lower half of its reported 52-week range, 41.51% below the high.
£0.01£0.00 (0.0%)
CelLBxHealth plc’s quoted price sits in the lower half of its reported 52-week range, 77.68% below the high.
£0.07£0.00 (0.0%)
Tissue Regenix Group plc’s quoted price sits in the lower half of its reported 52-week range, 89.02% below the high.
£0.01-£0.00 (-5.71%)
GENinCode plc’s quoted price sits in the lower half of its reported 52-week range, 86.53% below the high.
£0.01£0.00 (0.0%)
Cizzle Biotechnology Holdings Plc’s quoted price sits in the lower half of its reported 52-week range, 70.51% below the high.
£0.09£0.00 (0.0%)
CRISM Therapeutics Corporation’s quoted price sits in the lower half of its reported 52-week range, 52.7% below the high.
£0.00£0.00 (0.0%)
Nuformix plc’s quoted price sits in the lower half of its reported 52-week range, 81.08% below the high.
